STUDY QUESTION: How does a single dose of mifepristone on Day 2 after the LH peak (LH + 2) affect the endometrial receptivity transcriptome as assessed by the receptive signature established by the endometrial receptivity analysis (ERA)?
Introduction
Endometrial receptivity is defined as the specific time frame during progesterone-induced endometrial maturation when blastocyst implantation can occur. In a normal menstrual cycle, the endometrium is only receptive for about 24-36 h around Day 7 after the LH peak (LH + 7) or 5 days after progesterone administration (P + 5) in a hormonal replacement therapy cycle. This period is recognized as the window of implantation (WOI), regulated primarily by progesterone action and it might differ slightly between individuals (Ruiz- .
Based on the genetic information generated on the human endometrium in the last 15 years, our group developed a molecular diagnostic tool that can identify endometrial receptivity using a specific transcriptomic signature. The endometrial receptivity analysis (ERA) is composed of 248 genes analysed by next generation sequencing (NGS) and coupled to a computational predictor. It can identify the receptivity status of an endometrial sample to diagnose the personalized WOI (pWOI) of a given patient regardless of the sample's histological appearance (Diaz-Gimeno et al., 2011 Ruiz-Alonso et al., 2012) .
Endometrial receptivity is on the cutting edge of fertility but it is also an interesting target for contraception (von Grothusen et al., 2014) . Antiprogestogens or so called progesterone receptor modulators (PRMs) block the action of progesterone at the cellular level through binding to the progesterone receptor and thus impacting the initiation and course of pregnancy at the endometrial level. Mifepristone is a first-generation PRM that also binds with high affinity to the glucocorticoid receptor. It is approved in many countries for early firsttrimester medical abortion. It is also widely used for emergency contraception and for the treatment of symptomatic uterine fibroids (Murji et al., 2017) . In the context of contraception it has been shown that a single dose of 200 mg mifepristone in the immediate postovulatory phase is sufficient to prevent pregnancy by rendering the endometrium refractory or non-receptive but without interrupting the normal menstrual cycle (Gemzell-Danielsson et al., 1993 , 1994 . Treatment with mifepristone later in the secretory phase will result in endometrial breakdown, corpus luteum demise and endometrial shedding (Swahn et al., 1988) . Mifepristone treatment has also been shown to significantly modify endometrial gene expression (Boggavarapu et al., 2016a,b) and in an in vitro 3D endometrial cell culture model mifepristone inhibits embryo implantation (Lalitkumar et al., 2007; Boggavarapu et al., 2016a,b) .
Mifepristone treatment provides a system to identify progesteroneregulated genes that are involved in endometrial receptivity. In the present study, we aimed to study the effect of mifepristone on the human endometrial receptivity transcriptome in vivo using the ERA test.
Materials and Methods

Ethics
The study was approved by the regional ethics committee (EPN) in Stockholm, Sweden (Dnr: 00-133). Subjects were included after giving informed consent.
Sample collection and donors
Endometrial samples were obtained from a biobank affiliated with Karolinska University Hospital in Stockholm, Sweden. The samples used were collected in the years [2005] [2006] . Sample donors met the following inclusion criteria: proven fertile with at least one previous spontaneous pregnancy, free from gynaecological disease and otherwise healthy, and with no use of hormonal or intrauterine contraceptive for at least 3 months prior to inclusion.
Sample donors were instructed to monitor LH levels in urine from approximately cycle Day 10 by using a rapid self-test (Clearplan, Searle Unipath Ltd., Bedford, UK) to detect the LH-peak. Endometrial biopsies were collected from the upper part of the uterine cavity using a pipelle catheter (Prodimed, Neuilly en Thelle, France). Biopsies were obtained on day LH + 7 in natural cycles (n = 11) and at LH + 7 after treatment with 200 mg mifepristone on day LH + 2 (n = 7). Also, samples for comparison were obtained in natural cycle during the proliferative stage (n = 7).
Sample processing
Endometrial tissue samples were snap frozen with liquid nitrogen and stored in a biobank in liquid nitrogen under carefully monitored conditions until RNA extraction. RNA extraction from the tissue was performed using ZR BashingBead™ Lysis tubes (Zymo research) with 10 min shaking in 500 μl of zymo RNA microprep lysis buffer followed by RNA extraction with Quick-RNA microprep (Zymo Research) as per the manufacturer's instructions. All samples were treated with DNAse and stored in −80°C until further processing.
Endometrial receptivity analysis
All the samples were DNAse treated, and cDNA was obtained by retrotranscription and analysed by targeted RNA-Seq assay on IonTorrent Next Generation Sequencing, for 248 ERA genes in an Ion S5 system. Sequencing files were used as the input of the ERA predictor (Diaz-Gimeno et al., 2011) to quantify the expression of the ERA genes and to assess the endometrial receptivity status of each sample. Briefly, the reads were mapped to the hg19 human genome transcriptome using the STAR read aligner (Dobin et al., 2013) . To count the number of reads that could be assigned to each gene, we used the HTSeq tool (Anders et al., 2015) with the union option. The ERA gene counts were used by the prediction model to classify each sample in an endometrial receptivity class: proliferative, pre-receptive, receptive or post-receptive.
Transcriptomics analysis
The matrix containing the gene counts of all the samples was used for the downstream analysis in R (RDevelopmentCoreTeam, 2008) . We used the package ggplot2 (Wickham, 2009) to visualize the results. The differential expression analysis was done using edgeR package (Zhou et al., 2014) .
First, we filtered low expression genes and normalized the data using the TMM method. After the normalization step, we used the prcomp R function for a principal component analysis (PCA) in order to study the variability of the treated, control and proliferative groups (Fig. 1a-c) . Hierarchical clustering analysis using hclust R function with a complete method was Figure 1 Principal component analysis and heatmap of endometrial receptivity analysis (ERA) differentially expressed genes. Principal component analysis (a-c) shows how samples belonging to control 7 days after the LH surge (LH + 7) (C), LH + 7 treated with mifepristone (T) at LH + 2 or proliferative endometria (P), cluster separately based on the expression of the ERA genes. Data plots are presented in three dimensions showing the plane based on components 1 and 2 (a), components 1 and 3 (b) and components 2 and 3 (c). Percentages shown in the axis labels refer to the component variability. Heatmap (d) shows the expression level for the differentially expressed ERA genes in the three analysed groups. Annotations on top show the clustering of the samples using the Euclidean distance. The only sample from group T that was staged as pre-receptive (T7), clustered together with the other T samples rather than with samples staged similarly.
used to compute distance among the samples using the Euclidean approach (Fig. 1d) . We obtained the differential expressed genes for three comparisons: control versus treated, proliferative versus treated and control versus proliferative. We selected a gene as differentially expressed if logfold-change (FC) ≥ 2 and false detection rate (FDR) ≤ 0.01. All the differentially expressed genes were represented in a heatmap to visualize potentially different endometrial profiles (Fig. 1d ).
Network analysis
Gene network and pathway analysis based on differential gene expression was performed using the bioinformatics tool Ingenuity Pathway Analysis (IPA) software (Qiagen). All genes with their respective fold change were submitted into IPA and relevant receptors were selected to analyse how they were affected. 
Statistical analysis
Real time PCR data were checked for assumptions such as normality and homogeneity of variances. Based on the assumptions nonparametric Mann Whitney test was performed and all the statistical analysis was performed in Prism 6 (Graphpad, CA).
Results
Mifepristone modifies the transcriptomic signature of endometrial receptivity
We applied the ERA computational predictor to the sequencing results in order to explore how mifepristone affects the transcriptomic signature of endometrial receptivity. We found that in the control group all samples were diagnosed as would be clinically expected for LH + 7 with four samples as pre-receptive, three as receptive and four as late-receptive. In the mifepristone group, however, six samples were staged as refractory/proliferative and one as pre-receptive. Further, we investigated the modification of the endometrial signature induced by mifepristone treatment (T) (n = 7) by comparing them with proliferative (P) samples obtained in natural cycles (n = 7) and controls (C) at LH + 7 (n = 11). We utilized PCA to explore and visualize the differences in the transcriptomic profile among the three groups (Fig. 1) . PCA shows how samples are grouped based on three principal components (group of genes). Component 1 has higher weight (52.8%). Based on the plot created between components 1 and 2 (Fig. 1a) , there is a clear segregation among the three groups. Although mifepristone treatment and proliferative groups are closer to each other than to controls, they are not mixed as demonstrated when components 1 and 2 are analysed (Fig. 1a) , but also by components 1 and 3 (Fig. 1b) , and 2 and 3 (Fig. 1c) ; demonstrating distinct differences between these two groups.
To further explore the molecular relationship between the samples in the different groups we applied hierarchical clustering. We found that the three groups (C, P, T) separated clearly into different clusters (Fig. 1d) . Although the treatment group clustered closely with the proliferative samples, there was a hierarchal separation between them showing differences in their transcriptomic profiles. In this analysis, the only treatment sample that was staged as pre-receptive (T7), clustered together with the treatment group rather than with the pre-receptive samples from the control group, indicating a specific signature for the mifepristone treated group.
Specific endometrial gene signature induced by mifepristone treatment
We further wanted to explore which of the ERA genes were significantly deregulated by mifepristone treatment and how they differed in comparison to the naturally refractory samples obtained in the proliferative stage. We chose a stringent cut-off of logFC ≥ 2 and FDR ≤ 0.01 and applied to the comparison between LH + 7 endometria in the presence or absence of mifepristone treatment and identified 60 deregulated genes (Table I ). Gene expression comparison between the mifepristone LH + 7 group versus the proliferative group identified 24 genes differentially expressed (Table II ), indicating that although more similar to the proliferative group than to controls there is a distinct difference. Finally, when comparing proliferative versus LH + 7 samples without mifepristone, we found 93 differentially expressed genes (Table III) .
The heatmap (Fig. 1d) shows that in the LH + 7 control samples cluster there is a gradation based on different endometrial stages (from pre-receptivity to late receptivity), but all of them with a different profile than mifepristone treated and proliferative samples. In total, there were 42 genes with similar expression patterns in proliferative and mifepristone treated samples when compared to controls (Fig. 2) . From these 42 genes, 13 are activated and the remaining 29 are downregulated. However, there were 24 differentially expressed genes between proliferative and mifepristone treated samples, three of them also with differentially expression when compared with control samples, showing a specific expression pattern for each one of the three studied groups (CRABP2, PENK, PTPRR).
The transcriptomic differences between mifepristone treated samples versus LH + 7 controls were also observed in several pathways. As an example, the oestrogen signalling pathway shows downregulation in mifepristone treated versus control group ( Supplementary Fig. S1a ). This down-regulation is specific for the mifepristone effect, since this pathway is not differentially regulated between proliferative and control group (Supplementary Fig. S1b ).
qPCR validation
From the 60 genes differentially expressed between control and treatment we randomly selected five genes, CRABP2, MT1G, MT2A, POSTN and PROM1 that were up-and down-regulated to validate by qPCR. The results were in line with the sequencing results for all selected genes ( Supplementary Fig. S2 ).
Ingenuity pathway analysis
In order to explore the context of the deregulated genes in the treatment group, we utilized the software IPA (Qiagen). As expected for mifepristone action, the tool for upstream regulator prediction demonstrated that both the progesterone receptor (PGR) and the glucocorticoid receptor (NR3C1) were inactivated in the mifepristone treatment group (Fig. 3) . Interestingly, activation of the oestrogen receptor (ESR) was also predicted supporting the non-receptive/ refractory state of the endometrium treated with mifepristone.
Discussion
In this study, we demonstrate how at the transcriptional level a single dose of 200 mg of mifepristone on day LH + 2 induces a nonreceptive stage of the human endometrium by blocking both the progesterone and glucocorticoid receptor pathways. We found that the ERA computational predictor diagnosed all mifepristone treated samples but one as 'proliferative', whereas control samples were staged as 'receptive' or close to it, as expected. represents an endometrium that has not been exposed to progesterone, we expect that a pharmacological agent that inhibits the action of progesterone, such as mifepristone, provokes a similar response at gene expression level as naturally occurring proliferative endometrium. Further analysis from samples obtained at the proliferative stage demonstrated that the mifepristone treatment group was however different from the proliferative group, most probably due to the simultaneous blockage of the glucocorticoid receptor. This is in line with previous reports of mifepristone action that have clearly shown that mifepristone does not set the endometrium back to proliferative (Qiu et al., 2002) . However, it was clear that the treatment group was non-receptive, demonstrating the strength of ERA in identifying nonreceptive endometrium even under non-physiological conditions. In order to further study progesterone action we identified 60 genes that were differentially regulated under mifepristone action. Due to the fact that these genes were selected specifically from an endometrial receptivity signature (ERA), it is not surprising that our results confirmed previous studies in this context. In Bhagwat et al. (2013) 's database we can find SCGB2A2, GAST, MT1H, CXCL13, PAEP, CXCL14, SLC14A1, HAL, MFAP5, MAOA, DKK1 and CDA to be upregulated in the receptive phase of normal endometrium. Our data show significant down-regulation of all these genes after mifepristone treatment, indicating a disrupted gene profile. Similarly, TRH, GALNT12 and TACC3 were up-regulated after mifepristone treatment but are normally down-regulated in receptive phase (Bhagwat et al., 2013) . Several of the genes have also been previously reported as progesterone regulated including SFRP4 (Kao et al., 2002) , POSTN (Cheon et al., 2002) , S100P (Zhang et al., 2012) and CXCL14 (Mokhtar et al., 2010) . Interestingly, we can also note that downregulation of S100P and CXCL13, which were both down-regulated by mifepristone, have previously been associated with recurrent implantation failure (Choi et al., 2016) . Also, MT1G stands out as an interesting target for future research since it has a strong down-regulation. Hu et al. (2014) reported in 2014 that MT1G is normally up-regulated during implantation and a previous study from our team also showed down-regulation by mifepristone (Boggavarapu et al., 2016b) .
When comparing the refractory endometrial profile induced by mifepristone treatment with the one induced by an intrauterine device (IUD) previously reported by our group (Horcajadas et al., 2006) we can also make some interesting observations. From the 147 differentially expressed genes found in the comparison between LH + 7 with and without presence of IUD, 29 belong to the ERA gene panel. From these 29 genes, only four were found differentially expressed in the comparison between LH + 7 with and without mifepristone treatment. These four genes were up-regulated in the presence of an IUD but down-regulated with mifepristone treatment. This suggests that mifepristone and IUD's induce refractory endometrium through different actions; while IUD provokes a pre-receptive endometrium through a direct physical effect mifepristone blocks the progesterone receptor leading to a non-receptive gene expression profile resembling that of proliferative stage.
The strength of this study is the use of a commercially available test for endometrial receptivity to understand endometrial non-receptivity induced by mifepristone. Data mining beyond this effect gives our results strong relevance as a transcriptomic mirror for biologic events. Although ERA is based on a highly sensitive and accurate method of Figure 2 Venn diagram of the differentially expressed endometrial receptivity analysis (ERA) genes. Venn diagram showing the intersection among the differentially expressed genes obtained from the comparisons between the three groups: control group 7 days after the LH surge (LH + 7) (C), group treated with mifepristone on LH + 2 sampled at LH + 7 (T), control group of refractory/proliferative samples (P). Box plots showing expression levels for the three genes with significant differential expression (CRABP2, PENK, PTPRR) in the three compared groups are also shown.
gene expression analysis, we randomly picked a few genes to validate the results by qPCR.
The primary limitations of this study are the relative small number of subjects and the analysis of a defined endometrial gene signature composed of 248 genes. This might have prevented us from discovering genes and pathways previously not linked to progesterone receptor activation and endometrial receptivity. Our study however posts a significant contribution to validating the effectiveness and accuracy of the ERA method not only in the context of infertility but also in contraception. It shows that the ERA can be used to identify non-receptive endometrium under non-physiological conditions where progesterone action is inhibited and thus further expands its possible clinical and research use.
Supplementary data
Supplementary data are available at Human Reproduction online. expressed genes (control versus treatment) and the progesterone receptor (PGR), the glucocorticoid receptor (NR3C1) and the oestrogen receptor (ESR). Blue = predicted inactivation, orange = predicted activation, red = up-regulation and green = down-regulation.
